informCLL: A Disease Registry for Patients with Chronic Lymphocytic Leukemia

Purpose

To describe current treatment patterns in the real-world setting among CLL patients who are beginning treatment with approved oral kinase inhibitors or other approved anti-CLL therapies/regimens as well as any association with patient characteristics, healthcare resource utilization, clinical outcomes, & patient-reported outcomes.

Criteria

At least 18 years of age

Clinical diagnosis of Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL)

Beginning treatment within +/- 30 days of enrollment

Willing & able to provide written informed consent

Willing & able to complete patient reported outcome questionnaires

Willing & able to provide information on patient survey questionnaires

Willing to provide a blood sample at time of enrollment

You Cannot:           

Be diagnosed with any B-Cell malignancy other than CLL/SLL

Have a life expectancy of less than 6 months

Details

Relevant data will be retrieved from the patient medical record & recorded into the registry electronic case report forms along with the completion of the patient reported outcome quesationniare :

Baseline

Every 3 months for the 1st 6 months

Every 6 months thereafter for a minimum of 2 years





Interested in more information on this clinical research study?

Contact WK Cancer Center Clinical Research Department at 318-212-8671

Interested in more information? Contact Us:

Hematology Oncology Associates

IRB: Advarra Institutional Review Board
IRB Number:
Trial Type: NA
Sponsor: Pharmacyclics LLC